No Data
No Data
JonesTrading Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10
Oppenheimer Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $12
Aldeyra Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10
Optimistic Buy Rating for Aldeyra Therapeutics Amid Promising FDA Review and Potential AbbVie Collaboration
Institutional Investors in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) See US$94m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Unlock the Full List